NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

September 24, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

November 30, 2017

Conditions

Adenocarcinoma of the LungExtensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Non-small Cell Lung CancerRecurrent Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

Interventions

DRUG

Ponatinib

Ponatinib 45mg taken by mouth each day at the same time with or without food

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora